Michael Schrader
Internal Medicine · San Francisco, CANPI 1225140742
Payments from drug & device makers
Across 68 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$368
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$204
- Amarin Pharma, Inc.$171
- Merck$142
- Pfizer$101
- Shionogi Inc$95
- plus $371 from 8 others
What the payments were for
- Food & beverage$1,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 11 | $368 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $204 |
| Amarin Pharma, Inc. | 10 | $171 |
| Merck | 6 | $142 |
| Pfizer | 4 | $101 |
| Shionogi Inc | 4 | $95 |
| Viiv Healthcare Company | 3 | $95 |
| Amgen | 3 | $92 |
| AstraZeneca | 2 | $54 |
| GSK | 2 | $48 |
| Insmed, Inc. | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
How this compares
$1,453 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 112 | $117,719 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $40,564 |
| JanuviaSitagliptin Phosphate | 23 | $21,354 |
| TrulicityDulaglutide | 12 | $20,969 |
| OzempicSemaglutide | 15 | $16,360 |
| JardianceEmpagliflozin | 16 | $14,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $10,402 |
| FarxigaDapagliflozin Propanediol | 11 | $7,991 |
| Atorvastatin Calcium | 454 | $4,283 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $3,665 |
| Levothyroxine Sodium | 234 | $3,402 |
| Colchicine | 18 | $3,286 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,117 |
| Losartan Potassium | 274 | $2,952 |
| Dexlansoprazole DrDexlansoprazole | 15 | $2,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $101 | $119,148141 claims |
| Viiv Healthcare CompanyTriumeq | $95 | $40,56411 claims |
| MerckJanuvia | $142 | $21,35423 claims |
| AstraZenecaFarxiga, Symbicort | $54 | $11,10822 claims |
| GSKAnoro Ellipta | $48 | $10,40217 claims |
| AbbVieSynthroid | $12 | $1,30025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.